Granisetron hydrochloride syrup uses

Information about Granisetron Granisetron Uses Granisetron is used to prevent nausea and vomiting due to chemotherapy. How Granisetron works Granisetron granisetron hydrochloride syrup uses an antiemetic medication. It works by blocking the action of a chemical messenger serotonin in the brain that may cause nausea and vomiting during anti-cancer treatment chemotherapy or after surgery. Anuj Saini.

Official websites use. Share sensitive information only on official, secure websites. Granisetron is used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy. Granisetron is in a class of medications called 5-HT 3 receptor antagonists. It works by blocking serotonin, a natural substance in the body that causes nausea and vomiting.

Granisetron hydrochloride syrup uses

Chemotherapy-induced nausea and vomiting CINV , prevention:. Highly emetogenic chemotherapy:. Moderately emetogenic chemotherapy:. Low-emetogenic chemotherapy:. Consult drug interactions database for more information. For additional information see "Granisetron: Drug information". Note: Granisol oral solution has been discontinued in the United States for more than 1 year. Oral: 2 mg once daily up to 1 hour before chemotherapy or 1 mg twice daily; the first 1 mg dose should be administered up to 1 hour before chemotherapy with the second 1 mg dose 12 hours later. Administer only on the day s chemotherapy is administered. May also be administered in combination with a neurokinin 1 NK 1 receptor antagonist antiemetic regimen. Transdermal patch: Prophylaxis of chemotherapy-related emesis: Apply 1 patch at least 24 hours prior to chemotherapy; may be applied up to 48 hours before chemotherapy. Remove patch a minimum of 24 hours after chemotherapy completion. Maximum duration: Patch may be worn up to 7 days, depending on chemotherapy regimen duration. Guideline recommendations:. Day of chemotherapy: Administer prior to chemotherapy and in combination with an NK 1 receptor antagonist, dexamethasone, and olanzapine.

Refer to manufacturer's labeling. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. Postoperative nausea and vomiting, prevention off-label use : IV: 0.

Granisetron is a serotonin 5-HT 3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve , which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors. Granisetron was developed by chemists working at the British drug company Beecham c. It is produced by Roche Laboratories under the trade name Kytril.

This page contains brief information about granisetron and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials. FDA label information for this drug is available at DailyMed. Granisetron is approved to be used alone or with other drugs to prevent:. Granisetron is also available in a different form called granisetron hydrochloride. MedlinePlus Information on Granisetron - A lay language summary of important information about this drug that may include the following:. Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.

Granisetron hydrochloride syrup uses

Granisetron is a serotonin 5-HT 3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve , which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness.

Treasure hunt television show

Risk C: Monitor therapy. Oral: 2 mg Ref. Postoperative nausea and vomiting, prevention off-label use : IV: 0. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. Interactive image. Billio A ed. Extended-release SUBQ injection Sustol : Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy MEC or anthracycline and cyclophosphamide combination chemotherapy regimens FDA approved in adults. Serotonin receptor modulators. Eur J Cancer. However, some studies suggest that Granisetron is more effective than Ondansetron. Varun Gupta. Am J Pediatr Hematol Oncol. Stable for 91 days refrigerated Nahata Ask your pharmacist for a list of the ingredients.

Official websites use. Share sensitive information only on official, secure websites.

Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Published online April 28, Administer only on the day s chemotherapy is administered. Low-emetogenic brain, head and neck, thorax, pelvis or minimal-emetogenic extremities, breast risk radiation therapy: Routine prophylaxis not recommended; however, for radiation therapy to the head and neck, thorax, or pelvis, or for minimal emetogenic risk radiation therapy, may use as rescue therapy Ref. Agonists: 4-Methylaminorex Aminorex Amphetamines e. Refer to manufacturer's labeling. Granisetron comes as a tablet to take by mouth. Due to the ER properties of the SUBQ formulation, granisetron exposure may continue for 5 to 7 days following administration; hypersensitivity reactions may occur up to 7 days or longer following administration and may have an extended course. September 12, Neonatal deaths associated with use of benzyl alcohol—United States.